Hollsteen
← VeriSign

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 2016: $17.0M · 10-Q 0001014473-16-000101 filed Apr 28, 2016Research and development · Q2 2016: $14.0M · 10-Q 0001014473-16-000111 filed Jul 28, 2016Research and development · Q3 2016: $14.0M · 10-Q 0001014473-16-000117 filed Oct 27, 2016Research and development · Q4 2016: $14.0M · derived · 10-K 0001014473-18-000018 filed Feb 16, 2018Research and development · Q1 2017: $13.0M · 10-Q 0001014473-17-000012 filed Apr 27, 2017Research and development · Q2 2017: $14.0M · 10-Q 0001014473-17-000029 filed Jul 27, 2017Research and development · Q3 2017: $13.0M · 10-Q 0001014473-17-000048 filed Oct 26, 2017Research and development · Q4 2017: $13.0M · derived · 10-K 0001014473-19-000005 filed Feb 15, 2019Research and development · Q1 2018: $15.0M · 10-Q 0001014473-18-000028 filed Apr 26, 2018Research and development · Q2 2018: $14.0M · 10-Q 0001014473-18-000036 filed Jul 26, 2018Research and development · Q3 2018: $14.0M · 10-Q 0001014473-18-000040 filed Oct 25, 2018Research and development · Q4 2018: $15.0M · derived · 10-K 0001014473-20-000006 filed Feb 14, 2020Research and development · Q1 2019: $16.0M · 10-Q 0001014473-19-000015 filed Apr 25, 2019Research and development · Q2 2019: $15.0M · 10-Q 0001014473-19-000030 filed Jul 25, 2019Research and development · Q3 2019: $15.0M · 10-Q 0001014473-19-000037 filed Oct 24, 2019Research and development · Q4 2019: $15.0M · derived · 10-K 0001014473-21-000005 filed Feb 19, 2021Research and development · Q1 2020: $17.0M · 10-Q 0001014473-20-000019 filed Apr 23, 2020Research and development · Q2 2020: $18.0M · 10-Q 0001014473-20-000029 filed Jul 23, 2020Research and development · Q3 2020: $20.0M · 10-Q 0001014473-20-000034 filed Oct 22, 2020Research and development · Q4 2020: $19.0M · derived · 10-K 0001014473-22-000007 filed Feb 18, 2022Research and development · Q1 2021: $20.0M · 10-Q 0001014473-22-000016 filed Apr 28, 2022Research and development · Q2 2021: $20.0M · 10-Q 0001014473-22-000023 filed Jul 28, 2022Research and development · Q3 2021: $20.0M · 10-Q 0001014473-22-000027 filed Oct 27, 2022Research and development · Q4 2021: $21.0M · derived · 10-K 0001014473-23-000005 filed Feb 17, 2023Research and development · Q1 2022: $23.0M · 10-Q 0001014473-22-000016 filed Apr 28, 2022Research and development · Q2 2022: $20.0M · 10-Q 0001014473-22-000023 filed Jul 28, 2022Research and development · Q3 2022: $21.0M · 10-Q 0001014473-22-000027 filed Oct 27, 2022Research and development · Q4 2022: $22.0M · derived · 10-K 0001014473-24-000006 filed Feb 15, 2024Research and development · Q1 2023: $24.0M · 10-Q 0001014473-23-000019 filed Apr 27, 2023Research and development · Q2 2023: $22.0M · 10-Q 0001014473-23-000033 filed Jul 27, 2023Research and development · Q3 2023: $22.0M · 10-Q 0001014473-23-000038 filed Oct 26, 2023Research and development · Q4 2023: $23.0M · derived · 10-K 0001014473-25-000006 filed Feb 13, 2025Research and development · Q1 2024: $25.0M · 10-Q 0001014473-24-000023 filed Apr 25, 2024Research and development · Q2 2024: $24.0M · 10-Q 0001014473-24-000033 filed Jul 25, 2024Research and development · Q3 2024: $23.0M · 10-Q 0001014473-24-000040 filed Oct 24, 2024Research and development · Q4 2024: $25.0M · derived · 10-K 0001014473-26-000006 filed Feb 5, 2026Research and development · Q1 2025: $26.0M · 10-Q 0001014473-25-000021 filed Apr 24, 2025Research and development · Q2 2025: $26.0M · 10-Q 0001014473-25-000036 filed Jul 24, 2025Research and development · Q3 2025: $25.0M · 10-Q 0001014473-25-000046 filed Oct 23, 2025Research and development · Q4 2025: $26.0M · derived · 10-K 0001014473-26-000006 filed Feb 5, 2026Research and development · Q1 2026: $28.0M · 10-Q 0001014473-26-000020 filed Apr 23, 2026Research and development · Q2 2026: $28.0M · 10-Q 0001014473-26-000028 filed Jul 23, 202622.9a27.516.7Q1 2016Q2 2026Q4 2023
$MResearch and development · Q4 2022: $22.0M · derived · 10-K 0001014473-24-000006 filed Feb 15, 2024Research and development · Q1 2023: $24.0M · 10-Q 0001014473-23-000019 filed Apr 27, 2023Research and development · Q2 2023: $22.0M · 10-Q 0001014473-23-000033 filed Jul 27, 2023Research and development · Q3 2023: $22.0M · 10-Q 0001014473-23-000038 filed Oct 26, 2023Research and development · Q4 2023: $23.0M · derived · 10-K 0001014473-25-000006 filed Feb 13, 2025Research and development · Q1 2024: $25.0M · 10-Q 0001014473-24-000023 filed Apr 25, 2024Research and development · Q2 2024: $24.0M · 10-Q 0001014473-24-000033 filed Jul 25, 2024Research and development · Q3 2024: $23.0M · 10-Q 0001014473-24-000040 filed Oct 24, 202422.9a23.221.5a24.8Q4 2022Q3 2024Q4 2023
Q4 2023
22.9a$M
derived
All values (42)
PeriodValue ($M)Status
Q2 202627.5reported
Q1 202627.5reported
Q4 202526.5derived
Q3 202525.4reported
Q2 202525.7reported
Q1 202526.0reported
Q4 202424.9derived
Q3 202423.2reported
Q2 202423.8reported
Q1 202424.8reported
Q4 202322.9derived
Q3 202321.7reported
Q2 202322.2reported
Q1 202324.2reported
Q4 202221.5derived
Q3 202221.0reported
Q2 202220.3reported
Q1 202222.9reported
Q4 202120.8derived
Q3 202119.6reported
Q2 202119.8reported
Q1 202120.3reported
Q4 202019.4derived
Q3 202019.7reported
Q2 202018.2reported
Q1 202017.4reported
Q4 201915.1derived
Q3 201914.6reported
Q2 201915.0reported
Q1 201916.1reported
Q4 201815.0derived
Q3 201813.7reported
Q2 201813.8reported
Q1 201815.4reported
Q4 201712.8derived
Q3 201712.7reported
Q2 201713.5reported
Q1 201713.3reported
Q4 201613.7derived
Q3 201614.3reported
Q2 201614.3reported
Q1 201616.7reported

CSV with all sources · Technical ID: rnd

More metrics for VeriSign

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Sources & calculation
Value
$23.0M (derived)
Period
Q4 2023, ended Dec 31, 2023 · quarterly value (3 months, not cumulative)
Calculation
Q4 = fiscal year − 9 months cumulative = 91M − 68M = $23.0M (FY value from 10-K 0001014473-25-000006; 9-month value from the Q3-10-Q)
Source
10-K, filed Feb 13, 2025 · 0001014473-25-000006
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$23.0MFeb 13, 202510-K 0001014473-25-000006derived · confidence 1. · current